IC-MedTech, Inc. is a privately held California corporation formed in 2004. The company's mission is to achieve FDA approval of Apatone^®, a clinical phase investigational new drug. Currently under development for treatment of inflammatory periprosthetic aseptic osteolysis, Apatone is IC-MedTech's lead compound.

IC-MedTech in-licenses promising academic research and develops intellectual property, pre-clinical and clinical data necessary to develop the drug. The company collaborates closely with Summa Health Systems of Ohio and pharmaceutical drug collaborators. The Apatone Development Center located in St. Thomas Hospital (Akron, OH), manages and conducts basic research, preclinical and clinical studies examining drug safety and efficacy.

IC-MedTech owns exclusive rights to the US and international intellectual property and entered an exclusive worldwide supply alliance with a major international pharmaceutical manufacturer in August 2010. The company collaborates closely with Summa Health Systems of Ohio and strategic pharmaceutical drug manufacturers.

Inquiries: Robert Brewer, Esq, Jones Day - San Diego, CA.